JanOne Inc. (NASDAQ:JAN – Get Rating) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 23,400 shares, a decline of 34.8% from the March 15th total of 35,900 shares. Currently, 1.0% of the company’s stock are short sold. Based on an average trading volume of 48,600 shares, the days-to-cover ratio is currently 0.5 days.
A hedge fund recently bought a new stake in JanOne stock. Virtu Financial LLC acquired a new stake in JanOne Inc. (NASDAQ:JAN – Get Rating) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 15,886 shares of the company’s stock, valued at approximately $65,000. Virtu Financial LLC owned approximately 0.56% of JanOne at the end of the most recent quarter. Hedge funds and other institutional investors own 2.53% of the company’s stock.
Shares of JAN opened at $2.88 on Friday. The company has a quick ratio of 0.33, a current ratio of 0.39 and a debt-to-equity ratio of 0.51. The business’s 50 day moving average price is $3.16 and its 200-day moving average price is $4.27. JanOne has a 52 week low of $2.29 and a 52 week high of $12.28. The stock has a market cap of $8.15 million, a P/E ratio of -0.45 and a beta of 1.66.
JanOne Inc, a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain. It operates in three segments: Biotechnology, Recycling, and Technology.
- Get a free copy of the StockNews.com research report on JanOne (JAN)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for JanOne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JanOne and related companies with MarketBeat.com's FREE daily email newsletter.